New Study Reveals Limited Benefit of Chemotherapy for Rare Blood Cancer

Strategic Insights -

A recent multi-institutional study has analyzed 39 cases of anaplastic lymphoma kinase-positive large B-cell lymphoma (ALK+ LBCL), a rare and aggressive subtype of diffuse large B-cell lymphoma with poor outcomes using standard chemotherapy. Researchers from the University of Texas MD Anderson Cancer Center found that despite conventional cytotoxic regimens, outcomes remained poor, with a median event-free survival (EFS) of 0.6 years and median overall survival (OS) of 1.5 years.

Key Takeaways:

  • The study analyzed 39 cases of ALK+ LBCL identified at six US academic centers from 2002 to 2024.
  • Ninety-two percent of patients received frontline anthracycline-based chemotherapy, with 43% receiving intensified regimens and 15% undergoing upfront autologous stem cell transplantation (ASCT).
  • Advanced stage and high International Prognostic Index (IPI) scores were associated with inferior outcomes.
  • ALK inhibitors, including alectinib and crizotinib, showed more durable responses than chemotherapy, and lenalidomide and immune checkpoint inhibitors demonstrated activity, including durable complete responses.
  • Five patients underwent allogeneic stem cell transplantation, with three achieving sustained remission.

Statistics:

  • Median event-free survival (EFS) was 0.6 years (95% CI, 0.4-0.9).
  • Median overall survival (OS) was 1.5 years (95% CI, 1.3-NR).
  • One- and five-year EFS rates were 28% and 17%, respectively.
  • Corresponding OS rates were 72% and 42%, respectively.

Sources:

  • NewsRx. Reports from University of Texas MD Anderson Cancer Center Advance Knowledge in B-Cell Lymphoma (Multi-Institutional Study of ALK-Positive Large B-Cell Lymphoma: Outcomes in the Era of ALK Inhibitors and Biologically Informed Therapies). Hematology Week. September 15, 2025; p 2315.
  • Multi-Institutional Study of ALK-Positive Large B-Cell Lymphoma: Outcomes in the Era of ALK Inhibitors and Biologically Informed Therapies. American Journal of Hematology, 2025.